Despite many advances in the past years, the treatment of metastatic prostate cancer still remains challenging. In recent years, PSMA inhibitors were intensively studied in order to develop low molecular weight ligands for imaging prostate cancer lesions by PET or SPECT. However, the endoradiotherapeutic use of these compounds requires optimization with regard to the radionuclide-chelating agent and the linker moiety between chelator and pharmacophore which influence the overall pharmacokinetic properties of the resulting radioligand. In an effort to realize both detection and optimal treatment of prostate cancer, a tailor-made novel naphthyl-containing DOTA- 
INTRODUCTION
In western societies prostate cancer (PCa) continues to be the most common cancer in elderly men and the third most frequent cause of cancer-related mortality (1) . Consequently, there is a high clinical demand for more effective treatment options in case of metastatic and hormone-refractory prostate cancer.
Specific cancer targeting based on low molecular weight radioligands may offer a more accurate and rapid visualization, improved staging, and highly effective endoradiotherapy.
On the basis of small molecules, promising positron emission tomography As PSMA is strongly expressed in PCa and upregulated in poorly differentiated, metastatic and hormone-refractory carcinomas (7,8) it represents a highly attractive target in Nuclear Medicine potentially meeting the clinical requirements for an effective therapy of metastatic prostate cancer. In particular urea-based peptidomimetic inhibitors of PSMA were investigated mainly for by on . For personal use only. jnm.snmjournals.org Downloaded from diagnosis and shown to image advantageously PSMA-expressing prostate cancer (9) (10) (11) . Due to low expression levels in healthy tissue, however, PSMA has additionally the potential for high dose endoradiotherapy with minimized radioactivity related side-effects. Thus, a novel theranostic compound was designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) able to complex both 68 
An in vivo theranostic

Ga or 177
Lu, and a linker connecting these two entities. The linker turned out to be crucial for high imaging contrasts (14) as the chemical structure determines the internalization potency of the PSMA inhibitors (15) . Besides the targeting properties, modifications of the linker might also influence the pharmacokinetic properties of peptidomimetic PSMA inhibitors and, therefore, improve their therapeutic potential (16) . This study presents the preclinical evaluation of a tailor-made linker-optimized theranostic PSMA inhibitor with considerably optimized pharmacokinetic and targeting properties. Finally, the first individual clinical diagnostic experience with this novel radiotracer is shown underlining its clinical potential.
MATERIALS AND METHODS
All chemicals, reagents and solvents for the synthesis and analysis of the compound were analytical grade (for radiosynthesis ultrapure and metal-free), by on August 28, 2017. For personal use only. jnm.snmjournals.org Downloaded from purchased from Sigma Aldrich, Merck, Iris Biotech, or CheMatech and used without further purification.
The synthesis of PSMA-617 is summarized in Figure 1 . The peptidomimetic Glutamate-urea-Lysine binding motif (step 1 -6) and the linker was synthesized by solid-phase peptide chemistry as previously described (17) .
The conjugation of the chelator was performed using DOTA-tris(tBu)ester (see supplemental material for detailed synthesis information). The final product (PSMA-617) was cleaved from the resin and deprotected.
The compound (~42% yield) was analyzed and purified by RP-HPLC (Reversed-phase High-performance Liquid Chromatography) and MALDI-MS (Matrix-assisted Laser Desorption/Ionization Mass Spectrometry) (see supplemental material for detailed method information). 68 Ga [T 1/2 = 68 min, E β+,max = 1.9 MeV (88%)] was gained from a 68 Ge/ 68 Ga generator based on a pyrogallol resin support (18) as [ The binding affinity of PSMA-617 was assayed by enzyme-based (NAALADase) and cell-based competitive assays. Data obtained from both experiments were fitted using a nonlinear regression algorithm (GraphPad Prism 5) in order to obtain IC 50 (50% inhibitory concentration).
The NAALADase assay is based on a competitive reaction of recombinant human PSMA (rhPSMA; R&D Systems) with non-labeled PSMA-617 and was performed as previously described (17) were proved to be identical) and was additionally used as radioligand in the internalization assay. The assay was performed as described previously (19) (see supplemental material for detailed method information).
For µPET imaging with 68 Ga-labeled PSMA-617, a 50 min dynamic scan and a static scan from 100 to 120 min p.i. were performed (see supplemental material for detailed method information).
For organ distribution, the animals were sacrificed after indicated time points was performed as previously published (20) (21) (22) . The administered mass of [ 68 Ga]Ga-PSMA-617 was 2 µg. The administered activity was 288 MBq. There were no adverse or other clinically detectable pharmacological effects. No significant changes in vital signs were observed. The outcome from this study will be described in more detail in a further publication.
RESULTS
The chemical analysis is summarized in Table 1 . PSMA-617 is stable for at least 6 months as a lyophilized fluffy white powder and also in a solution of DMSO-d6, both at -20 °C, as shown by RP-HPLC and MALDI-MS. A precursor amount of 0.5 nmol was labeled with radiogallium with a RCY of >90 % in 15 min at 95 °C, for both 67 Ga or 68 Ga. µPET imaging was performed after purification by means of solid phase extraction using SepPak C18 cartridges (Waters). Higher amount of precursor (5 nmol For determination of the radiolytic stability, PSMA-617 was radiolabeled with 68 Ga or 67 Ga and incubated at 37 °C for 1 or 24 hours, respectively, both in PBS and in human serum. [ The µPET slices ( Figure 3A ,B,C,D) reveal an increasing tumor uptake up to 2 hours post injection and a rapid elimination of radioactivity from other organs, muscles and blood. The rapid kidney excretion is also demonstrated by the maximum intensity projection (MIP) scans ( Figure 4A,B) , whereby tumor uptake is maintained (see also Figure 2 ).
Organ distribution with 68 Ga-labeled PSMA-617 after 1 hour (n=3; Figure 5A Lu presents a lower proportion of γ-radiation which results in a considerably reduced hospitalization which goes along with improved radiation protection and lowered hemotoxicity (25) .
In general, theranostics based on radiometals offer targeted and personalized treatment for the patient while minimizing the damage of healthy tissues. From an economic point of view, in vivo theranostics yield an improved outcome for cancer patients, clinical trials can be designed more effectively and efficiently, and finally, individual costs for cancer treatment will be reduced.
Recently, 68 Ga-labeled Glu-urea-Lys-(Ahx)-HBED-CC ([ 68 Ga]Ga-PSMA-11) proved to be a very successful tracer for PET-imaging of recurrent prostate cancer (17) . It was reported that the chelator HBED-CC seems to interact advantageously with the lipophilic part of the PSMA binding pocket (17, 22) .
However, due to the high selectivity of the complexing agent HBED-CC for 68 Ga the radiotracer is not suitable for radiolabeling with therapeutic radiometals such as Thus, an ideal linker length (26) , polarity (27) , size, flexibility (28) , presence of aromatic groups (26) and/or hydrophobic functionality distal to the glutamic acid moiety (29) represents an effective strategy to design highly potent PSMA inhibitor based radiotracers.
Based on these considerations, a DOTA-conjugate of a PSMA inhibitor with optimized targeting properties has been designed in this study. The resulting by on August 28, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
